Podcasts about Carcinoid

A slow-growing type of neuroendocrine tumor that sometimes causes paraneoplastic syndromes

  • 35PODCASTS
  • 62EPISODES
  • 34mAVG DURATION
  • 1MONTHLY NEW EPISODE
  • Apr 15, 2025LATEST
Carcinoid

POPULARITY

20172018201920202021202220232024


Best podcasts about Carcinoid

Latest podcast episodes about Carcinoid

Ingest
Neuroendocrine Cancer - The Expert Patient

Ingest

Play Episode Listen Later Apr 15, 2025 43:29


The episode features Dr. David Bartlett, a retired GP and neuroendocrine cancer patient, offering a dual perspective as both clinician and patient.Key Learnings from this episode.Patient Experience and Diagnostic ChallengesDr. Bartlett's symptoms began with severe, intermittent abdominal pain, starting in 2001, but he did not seek medical help for several years due to a combination of stoicism, not wanting to trouble others, and a belief in the commonality of benign causes. Over 15 years, he experienced repeated misdiagnoses, primarily being labeled as having irritable bowel syndrome (IBS) despite atypical features (severe pain, minimal bowel habit change, and no systemic symptoms). Multiple opinions and investigations (including ultrasounds and CT scans) failed to identify the underlying cause, with a key scan being misread by local radiologists. The correct diagnosis of a small bowel neuroendocrine tumour was only made after a tertiary centre re-examined previous scans, highlighting the importance of specialist review and persistence in unexplained cases.Clinical Red Flags and SymptomatologyDr. Bartlett's case underscores that neuroendocrine tumors can present with isolated, severe abdominal pain without classic red flags (vomiting, weight loss, significant bowel changes)[1]. He retrospectively identified subtle signs of carcinoid syndrome (flushing, one episode of profound diarrhoea, and skin changes), which are present in only about 10% of small bowel neuroendocrine tumour cases. The lack of awareness about neuroendocrine tumors, even among experienced clinicians, contributed to the diagnostic delay[1].Lessons for Primary Care and CliniciansThe story illustrates the risk of anchoring on common diagnoses (like IBS) and the need to reconsider the diagnosis when symptoms are severe, persistent, or atypical. It highlights the value of listening to the patient's narrative, especially when symptoms do not fit classic patterns, and the importance of considering rare conditions in the differential diagnosis. The episode emphasises the need for ongoing education about neuroendocrine tumours and the importance of keeping rare but serious conditions on the diagnostic radar in primary care.Management InsightsStandard treatment for small bowel neuroendocrine tumours often includes monthly somatostatin analog injections (e.g., lanreotide). Surgical intervention may be considered, but it carries specific risks such as carcinoid crisis, requiring specialised perioperative management. The decision for surgery is individualised, weighing potential symptomatic improvement against procedural risks.Systemic and Human FactorsDr. Bartlett's experience reflects how personal traits (stoicism, reluctance to seek help) and systemic issues (misinterpretation of scans, diagnostic inertia) can delay diagnosis. The narrative also demonstrates the importance of patient advocacy, persistence, and the value of second (or third) opinions, especially in complex or unresolved cases.Educational ValueThe episode serves as a reminder for clinicians to maintain a broad differential, revisit diagnoses when the clinical picture changes, and to be aware of their own cognitive biases. It also advocates for the inclusion of patient voices in medical education to better understand the lived experience and challenges of rare diseases like neuroendocrine cancer.Summary Table: Key LearningsThemeKey PointsDiagnostic Delay15 years from symptom onset t... Chapters (00:00:10) - Ingest(00:02:07) - David Bartlett on neuroendocrine cancer(00:05:32) - Irritable bowel syndrome, 15 years after first bout(00:12:09) - Carcinoid syndrome in small bowel neuroendocrine tumors(00:16:10) - Neuroendocrine tumour, surgery and recovery(00:20:43) - Somaostatin analogues for neuroendocrine cancer(00:25:43) - The role of the multidisciplinary team in bowel cancer care(00:28:21) - The battle with depression in your 50s(00:30:00) - General Practice and the Art of Medicine(00:33:13) - General Practice: The challenge of slowing down(00:35:35) - Neuroendocrine Cancer UK support group(00:39:28) - David's story of cancer(00:40:38) - David's Neuroendocrine Cancer Episode 1

The LACNETS Podcast - Top 10 FAQs with neuroendocrine tumor (NET) experts

What is Carcinoid Heart Disease (CHD)? Which NET patients develop CHD?  Retired cardiologist and carcinoid heart disease specialist Dr. Jerome Zacks provides an overview of CHD and describes the appropriate screening, diagnosis, and treatment. MEET DR. JEROME ZACKSDr. Jerome Zacks is a Cardiologist/Carcinoid Heart Disease Specialist; retired since December of 2021; but remain active as Associate Clinical Professor of Medicine at the Icahn Medical School at Mount Sinai in New York City and founding member of the Center for Carcinoid and Neuroendocrine Tumors at the Icahn Medical School at Mount Sinai; founder of the Carcinoid Heart Center; formerly on the Medical Advisory Board of the Carcinoid Cancer Foundation;  currently head the Electrocardiography course for the 4th Year Medical Student elective at the Mt. Sinai Medical Center which has resulted in an international reputation among students seeking Cardiology training in the United States.  He has expertise in matters of health care Insurance Carriers' theft of funds from the Medicare program, has studied patterns of abuse in the Medicaid program and has extensive knowledge of pharmaceutical company abusive practices. Dr. Zacks continues to devote time to the care of patients with Carcinoid Heart Disease. He has served as a member of the Guidelines Committees of the European Neuroendocrine Tumor Society (ENETS) and of the North American Neuroendocrine Tumor Society (NANETS).   He developed a new approach to compression stockings for patients with leg edema; he was granted a patent for this innovation.  He has authored two national petitions urging Congress to mandate that any health care professional who uses one's license, in making decisions which influence a patient's care, be held to the SAME STANDARD OF CARE as the patient's treating professional. (These two petitions were blocked by Senator Cory Booker.)  In his role as patients' physician, he has attempted to remove barriers of communication.  His business card includes his personal mobile phone number as well as his email address and website information; He encourages patients to phone for immediate answers to urgent matters.  Along with his wife, Yelena - an RN- they have devoted their professional lives to patients with heart disease from rare Neuroendocrine tumors. They have mentored 5 children, and are now learning from them and their 6 grandchildren have provided the real fuel and excitement for their lives.For more information, visit https://www.ncf.net/podcast/43For more information, visit LACNETS.org.

The Medbullets Step 2 & 3 Podcast
Oncology | Carcinoid Syndrome

The Medbullets Step 2 & 3 Podcast

Play Episode Listen Later Feb 19, 2025 12:26


In this episode, we review the high-yield topic⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Carcinoid Syndrome⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠from the Oncology section at ⁠⁠⁠⁠⁠⁠Medbullets.com⁠⁠⁠⁠⁠⁠Follow⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Medbullets⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ on social media:Facebook: www.facebook.com/medbulletsInstagram: www.instagram.com/medbulletsofficialTwitter: www.twitter.com/medbulletsLinkedin: https://www.linkedin.com/company/medbullets

The LACNETS Podcast - Top 10 FAQs with neuroendocrine tumor (NET) experts
EPISODE 41: Top 10 Highlights of the 2024 NANETS Symposium

The LACNETS Podcast - Top 10 FAQs with neuroendocrine tumor (NET) experts

Play Episode Listen Later Feb 4, 2025 48:35


In this special episode, Oregon Health & Sciences University (OHSU) Medical oncologist Dr. Guillaume (Will) Pegna recaps the North American Neuroendocrine Tumor Society (NANETS) 2024 Multidisciplinary NET Medical Symposium. He shares the latest developments in NET research and medical advances from the conference and how they matter to the NET patient community.MEET DR. GUILLAUME PEGNADr. Pegna is a medical oncologist specializing in caring for adults with neuroendocrine tumors (NETs). He is additionally interested and experienced in the management of rare tumors, including pheochromocytomas, paragangliomas and adrenocortical carcinomas, as well as other gastrointestinal cancers.Dr. Pegna is actively involved with clinical trials and cancer research to improve survival and quality of life for cancer patients and to better understand the biology of these diseases. He specializes in the use of chemotherapy, immunotherapy and multidisciplinary approaches to cancer care. Dr. Pegna finds it rewarding to help patients understand their disease, providing treatment options based on each individual patient and supporting them through their treatment journeys.For more information, visit LACNETS.org/podcast/41. For more information, visit LACNETS.org.

The Nugget Climbing Podcast
EP 257: Sol Wertkin — Surviving Cancer, a Richer Life After Climbing, and Saying Goodbye to Johnny G.

The Nugget Climbing Podcast

Play Episode Listen Later Jan 27, 2025 188:00


Sol Wertkin is a former rock climber, cancer survivor, nurse, and avid mountain biker. We talked about new routing in the PNW, the “Golden Era” of Leavenworth climbing, the passing of Johnny Goicoechea, Sol's cancer diagnosis in 2020, the long and difficult road to recovery, how e-biking saved his life, sailing, why life feels richer now that he doesn't climb, and nuggets to help your own health journey.Feel free to message Sol on Instagram if you have any questions about cancer diagnosis or long covid. AG1:drinkAG1.com/NUGGETUse this link to get a free year's supply of vitamin D + 5 travel packs.Arc'teryx:Women's climbing clothingMen's climbing clothingCheck out the Psiphon and Serratus Alpine Kits launching January 15th.Rúngne:rungne.info/nugget

The LACNETS Podcast - Top 10 FAQs with neuroendocrine tumor (NET) experts
Episode 40: External Radiation Therapy for Neuroendocrine Cancers

The LACNETS Podcast - Top 10 FAQs with neuroendocrine tumor (NET) experts

Play Episode Listen Later Dec 22, 2024 53:11


ABOUT THIS EPISODEWhat is radiation oncology, and how is it used for neuroendocrine cancer? UCSF radiation oncologists Dr. Will Chen and Dr. Alexandra Hotca-Cho describe external radiation therapy (SBRT) and how, when, and where it may be used for select patients with neuroendocrine cancers. They address common concerns about the planning process, safety concerns, and treatment sequencing.TOP TEN QUESTIONS ABOUT EXTERNAL RADIATION THERAPY FOR NEUROENDOCRINE CANCERS:1. What is radiation oncology? How does it work? How is it different from other types of radiation?2. What are the types of radiation therapies used for neuroendocrine cancer? 3. Which neuroendocrine cancers are they used for, and when are they used? How do you decide who is a good candidate and if it will be effective?Where in the body can SBRT be used? (bone, liver, pancreas, rectal?) Where can it not be used in the body, and when is SBRT NOT used?Is there a number or size limit of the tumor(s)?4. For Bone: How do NETs affect the bones? Are they “on” or “in” the bone, and does the tumor tend to weaken it?If given to the bone, does SBRT weaken the bone? What are the chances of fracture with radiation to the bone? Does it matter which area of the bone/body is treated? What other factors influence fracture risk? (age, dose, number of treatments)? Should patients have a bone density scan before SBRT?If bone lesions are causing pain, how soon after treatment might a patient expect to have pain alleviated?How common is increased pain after treatment to the bone? What causes that?5. Safety: How much radiation is given with these procedures? Is there a concern about radiation safety following the procedures? (Do patients need to avoid others in the hours or days after the treatment?)Is there a lifetime limit to the amount of radiation one can receive, especially considering surveillance CT & PET scans?How often can these procedures be repeated? Does it damage other tissues or organs? How common are secondary cancers? What types and how treatable are they?Is there a risk with fertility?What other risks are there?6. How do these therapies compare to PRRT or radioembolization in terms of safety? If someone has had PRRT or radioembolization, can they also receive radiation therapy to the liver or bones? Is there increased risks if someone has had PRRT, radioembolization or CAPTEM or alkylating agents? 7. Is there an optimal sequence for treatments? 8. What is SBRT like for patients? What is the planning and preparation process? How do you determine how many treatments and what dose to give?9. What does the patient experience during and after the procedure? Does it hurt? What are the side effects? How much time do I need to take off of work? 10. How effective is SBRT in terms of managing symptoms? How effective is SBRT in controlling or destroying the tumor?  How do you know if the treatment “worked”?Bonus: What is the future of radiation therapy in neuroendocrine cancer treatment?For more information, visit LACNETS.org.

The LACNETS Podcast - Top 10 FAQs with neuroendocrine tumor (NET) experts
EPISODE 39: NEN TREATMENTS: FOCUS ON LIVER-DIRECTED THERAPIES (Part II: Intra-Arterial Techniques and Sequencing)

The LACNETS Podcast - Top 10 FAQs with neuroendocrine tumor (NET) experts

Play Episode Listen Later Nov 17, 2024 47:47


ABOUT THIS EPISODEIn this 2-part series, Dr. Osman Ahmed from the University of Chicago covers liver-directed therapies for neuroendocrine neoplasms (NENs or neuroendocrine cancer). In this second episode, he details the embolization techniques, including bland embolization (TAE), chemoembolization (TACE), and radioembolization (TARE, SIRT, y90). He discusses decision-making, sequencing, and follow-up after these procedures.TOP TEN QUESTIONS ABOUT LIVER-DIRECTED THERAPY PART 2:1. What do patients need to know about bland embolization (TAE)? a. What are the possible side effects? b. How do the size of beads play a role? c. When is this recommended? d. Do you always do both sides of the liver? If so, what is the timing and why? e. What is the recovery like? What is post-embolization syndrome?2. What do patients need to know about chemoembolization (TACE)?a. What drug is used & does this go through the whole body? b. What is the recovery like? What are the possible side effects?3. What do patients need to know about radioembolization (TARE, SIRT, y90)? a. In the era of PRRT, is there a concern with using y90 or radioembolization? How is the approach and technique used with radioembolization different than how it was done in the past? Is there a total lifetime limit of radiation?b. What is the recovery like? What are the possible side effects?4. Is there a limit to how much LDT one can do? Can they be repeated?5. How does one decide between the various types of liver-directed therapies?6. Is there a sequencing to treatments?7. Are there certain treatments that make you ineligible for other treatments? [PRRT, chemo, y90 etc] 8. If someone has had surgery such as a Whipple or surgery or procedures involving the bile duct, such as a stent in the bile duct or surgical removal of part of the bile duct, how does this weigh into the decision-making process for LDT?9. How do you determine if the treatment “worked?” What is the follow-up like? What scan might you do and in what timing?10. What do you see as the future of liver-directed therapy in neuroendocrine cancer treatment? MEET DR. OSMAN AHMEDOsman Ahmed, MD, is an expert vascular and interventional radiologist who diagnoses and treats a wide range of conditions. Using image-guided technology and small, sophisticated instruments, Dr. Ahmed performs minimally invasive procedures for acute and chronic deep vein thrombosis, benign prostatic hyperplasia, peripheral vascular disease, liver/bone/lung/kidney cancer, spinal fractures, uterine fibroids and more. He also implants inferior vena cava (IVC) filters, which prevent a blood clot from traveling around the body or creating a blockage.In addition to his clinical expertise, Dr. Ahmed researches novel treatment options that improve outcomes for patients. His research on liver cancer, IVC filters and venous diseases has been published in several high-impact, peer-reviewed journals, including the Journal of Vascular and Interventional Radiology, Radiology, Chest, Journal of American College of Radiology, and Journal of Surgical Oncology.Dr. Ahmed also believes in the importance of educating medical students, residents, fellowships and peers in order to enhance health care across the world. He has been invited to speak at a number of symposiums, practicums and national/international meetings about the newest advancements in interventional radiology.For more information, visit https://www.lacnets.org/lacnets-podcastFor more information, visit LACNETS.org.

The LACNETS Podcast - Top 10 FAQs with neuroendocrine tumor (NET) experts
Episode 38 - NEN Treatments: Focus on Liver-Directed Therapies (Part I: Overview and Ablative Techniques Including Histotripsy)

The LACNETS Podcast - Top 10 FAQs with neuroendocrine tumor (NET) experts

Play Episode Listen Later Oct 21, 2024 31:31


ABOUT THIS EPISODEIn this 2-part series, Dr. Osman Ahmed from University of Chicago covers liver-directed therapies for neuroendocrine neoplasms (NENs or neuroendocrine cancer). In this first episode, he outlines the types of liver-directed therapies and elaborates on ablative techniques including the newest technique, histotripsy. Listen to a frank discussion of how histotripsy works, when it might be used, and what its current limitations are.TOP TEN QUESTIONS ABOUT LIVER-DIRECTED THERAPY INCLUDING HISTOTRIPSY:What is liver-directed therapy? How does it work? Is this considered “surgery”? What is a surgery and what is a “procedure?”What are the types of liver-directed therapies used for neuroendocrine cancer? Which neuroendocrine cancers are they used for and when are they used? How do you decide who is a good candidate and if it will be effective?When are liver-directed therapies NOT used? Can someone who has had a Whipple undergo liver-directed therapy?What is the ablation zone? What is a heat sink effect?What is histotripsy? How does it work?When is histotripsy used (tumor grade, type of tumor - PNET/lung NET, size, number of tumor, location)? Can they be used for liver tumors even if there are tumors outside the liver?What are the limitations to histotripsy? What happens to the liver tissue after ablation? What are the results or success rates of patients being treated? Can histotripsy “cure” NET? How do you decide between the various types of liver-directed therapies? MEET DR. OSMAN AHMED:Osman Ahmed, MD, is an expert vascular and interventional radiologist who diagnoses and treats a wide range of conditions. Using image-guided technology and small, sophisticated instruments, Dr. Ahmed performs minimally invasive procedures for acute and chronic deep vein thrombosis, benign prostatic hyperplasia, peripheral vascular disease, liver/bone/lung/kidney cancer, spinal fractures, uterine fibroids and more. He also implants inferior vena cava (IVC) filters, which prevent a blood clot from traveling around the body or creating a blockage.In addition to his clinical expertise, Dr. Ahmed researches novel treatment options that improve outcomes for patients. His research on liver cancer, IVC filters and venous diseases has been published in several high-impact, peer-reviewed journals, including the Journal of Vascular and Interventional Radiology, Radiology, Chest, Journal of American College of Radiology, and Journal of Surgical Oncology.Dr. Ahmed also believes in the importance of educating medical students, residents, fellowships and peers in order to enhance health care across the world. He has been invited to speak at a number of symposiums, practicums and national/international meetings about the newest advancements in interventional radiology.Visit lacnets.org/podcast/38 for the podcast, transcript, and resources. For more information, visit LACNETS.org.

The LACNETS Podcast - Top 10 FAQs with neuroendocrine tumor (NET) experts
Episode 37: Supportive Oncology for Neuroendocrine Cancer

The LACNETS Podcast - Top 10 FAQs with neuroendocrine tumor (NET) experts

Play Episode Listen Later Sep 17, 2024 42:58


What is supportive care or supportive oncology? What is cancer-related distress? How might NET patients benefit from supportive care? Yale oncologist Dr. Maryam Lustberg suggests strategies to manage cancer-related fatigue, diarrhea, nausea, mouth sores, peripheral neuropathy, distress, anxiety, and anxiety. She also addresses considerations for fertility and sexual health.MEET DR. MARYAM LUSTBERGDr. Maryam Lustberg is an American breast oncologist. She is the Director of The Breast Center at Smilow Cancer Hospital and Chief ofBreast Medical Oncology at Yale Cancer Center. Dr. Lustberg previously served as the Medical Director of Cancer Supportive Care Services atOhio State's Comprehensive Cancer Center. She is the Immediate Past President of the Multinational Association of Supportive Care in Cancer. She is also an Associate Editor for the Journal of Cancer Survivorship.TOP TEN QUESTIONS ABOUT SUPPORTIVE CARE: What is supportive care in cancer (or supportive oncology)? What is survivorship? How do these concepts apply to the NET community?What is the 1st step for patients to get supportive care?What are the most common treated-related adverse events or side effects? What are risk factors for them? (Will all patients experience all potential side effects?)What causes cancer-related fatigue (CRF)? What are some strategies to manage cancer-related fatigue?What are some strategies to manage diarrhea?What are some strategies to manage nausea?What are some strategies to manage mouth sores?What is peripheral neuropathy? When do patients experience it and what can be done to prevent it?What should patients understand about sexual health and fertility?How can psychosocial needs such as distress, anxiety, and depression be addressed and supported?For more information, please visit https://www.lacnets.org/podcast/37. For more information, visit LACNETS.org.

All Things Cardio Oncology
Quality Improvement: Cardio-Oncology Clinic Screening for Carcinoid Heart Disease

All Things Cardio Oncology

Play Episode Listen Later Sep 2, 2024 30:24


Dr. Gagan Sahni Director of Cardio- Oncology and Inpatient Cardiology Consult services at Mount Sinai Hospital in NYC, and Fellow of ICOS presents her Center of Excellence quality improvement project.

NETs Get Real
NETs Get Real - Dr. Shikha Jain Returns to Discuss Carcinoid Heart Disease!

NETs Get Real

Play Episode Listen Later Aug 14, 2024 35:50


This episode we speak with the returning oncologist from the University of Illinois Cancer Center, Dr. Shikha Jain. She talks all about Carcinoid Heart Disease! Please make sure to follow us on your preferred streaming platform and give us a 5 star rating!For more information please go to our website: http://www.netcancerawareness.org and follow us on social media @netcanceraware

The LACNETS Podcast - Top 10 FAQs with neuroendocrine tumor (NET) experts
EPISODE 35 - NEN Treatments: Focus on Chemotherapy

The LACNETS Podcast - Top 10 FAQs with neuroendocrine tumor (NET) experts

Play Episode Listen Later Jul 24, 2024 36:38


What is chemotherapy? When are they used for neuroendocrine neoplasms (NENs)? Dr. Pamela Kunz from Yale Medicine discusses the benefits, potential side effects and latest advances in chemotherapy for NENs. She explains how it differs from other treatments for NENs and how she counsels patients as they consider chemotherapy.TOP TEN QUESTIONS ABOUT CHEMOTHERAPY FOR NENS:What is chemotherapy? How does it work? What are the chemotherapy drugs used for neuroendocrine cancer? When are they used? Which neuroendocrine cancers are they used for? How does chemotherapy differ from other treatments such as SSAs or targeted therapies (everolimus, sunitinib, cabozantinib)? What side effects might someone have when taking chemotherapy? Will my hair fall out? How might it affect my day-to-day ability to work and function? Can I live a “normal life” while taking this medication? Do any of these side effects have long-lasting effects?Would taking chemotherapy cause someone to be immunocompromised?When in one's neuroendocrine journey might you recommend chemotherapy? Where does it fall in sequencing?How do you decide which chemotherapy medication to recommend? Can they be stopped and restarted? Can they be repeated? Can you take more than one drug in the category? Can they be taken in combination with another drug?Does taking chemotherapy preclude someone from getting another treatment in the future such as Lutathera PRRT or a clinical trial of alpha PRRT?What do you see as the future of chemotherapy in neuroendocrine cancer treatment? MEET PAMELA L. KUNZ, MDDr. Pamela Kunz is an Associate Professor of Medicine in the Division of Oncology at Yale School of Medicine where she also serves as the Director of the Center for GI Cancers and Division Chief of GI Medical Oncology at Yale Cancer Center and Smilow Cancer Hospital. She received her medical degree from the Dartmouth Geisel School of Medicine. Her postgraduate training included a medical residency, chief residency, and oncology fellowship at Stanford University School of Medicine. Dr. Kunz is an international leader in the treatment and clinical research of patients with GI malignancies and neuroendocrine tumors (NETs). She holds several key leadership positions in the field including President Emeritus of the North American Neuroendocrine Tumor Society, recent past Chair of the Neuroendocrine Tumor Taskforce of the NCI and standing member of FDA's Oncology Drug Advisory Committee. She was recently appointed Editor-in-Chief of JCO Oncology Advances. In addition to her focus on NETs, she is a leading voice for promoting diversity, equity and inclusion in medicine. She served as the Vice Chief of DEI for the Section of Medical Oncology at Yale School of Medicine and in 2021, she was awarded ‘Woman Oncologist of the Year' by Women Leaders in Oncology for her work in promoting gender equity.For more information, visit LACNETS.org.

The LACNETS Podcast - Top 10 FAQs with neuroendocrine tumor (NET) experts

What is PRRT? How is it different from the more commonly used radiation treatment? What are the possible side effects? Dr. Riham El Khouli from the University of Kentucky in Lexington discusses common questions and concerns about PRRT and shares some of the latest advances.MEET DR. RIHAM EL KHOULI, MD, PHDAssociate Professor of Radiology, UK College of MedicineChief, Division of Nuclear Medicine/Molecular Imaging & Radiotheranostics (NM/MI&R)Director, Radiotheranostics ProgramUniversity of KentuckyDr. Riham El Khouli, MD PhD, is the director of the Radiotheranostics program and Chief of the division of NM/MI&R at the University of Kentucky and an Associate Professor of Radiology, Nuclear Medicine and Molecular Imaging at UK school of Medicine.TOP TEN QUESTIONS ABOUT NET TREATMENTS:1. What is PRRT?  How does it work? 2. What is theranostics and what does it mean? What are the terms radiotheranostics, radiopharmaceutical, radioligand therapy, PRRT?3. How do you determine who is eligible for PRRT?4. When is PRRT given in one's treatment journey? 5. How does PRRT differ from other treatments?6. What are the common side effects of Lutathera?a. Does Lutathera have long-lasting effects?b. Would receiving Lutathera affect one's blood counts?c. How might Lutathera affect one's liver function? When, if ever is there concern about liver failure?7. How might PRRT affect my quality of life and my day-to-day ability to work and function? What is the risk and effects of radiation with receiving Lutathera? a. What precautions do I need to follow?b. Can I hug my child? Can I pet my dog? c. Would receiving Lutathera cause someone to be immunocompromised? 8. How to you decide who should get PRRT?a. What is peritoneal disease and how effective is PRRT with peritoneal disease?9. How do you assess the response to PRRT? 10. What advances in PRRT are you most excited about? Visit https://www.lacnets.org/podcast/34. For more information, visit LACNETS.org.

The LACNETS Podcast - Top 10 FAQs with neuroendocrine tumor (NET) experts

ABOUT THIS EPISODEWhat are Targeted Therapies and how do they work? How and when would they be used in NETs? Dr. Scott Paulson from Baylor Cancer Center in Dallas discusses common questions and concerns about targeted therapies including side effects, dosing and treatment sequencing. Bonus: Dr. Paulson shares how we can learn from Harry Potter's invisibility cloak in understanding treatment goals with NETs.MEET DR. SCOTT PAULSONDr. Paulson is a medical oncologist and the medical director for the Neuroendocrine Research and Treatment Center at Baylor Charles A. Sammons Cancer Center in Dallas, Texas. He also serves as the co-director of the Gastrointestinal Research Program for the Sarah Cannon Research Institute.Dr. Paulson earned his medical doctorate at The University of Texas Southwestern Medical School. He took his residency and an internship in internal medicine at Brigham and Women's Hospital in Boston, Massachuests. His fellowship was completed in medical oncology at the University of California, San Francisco.  Dr. Paulson is active in clinical research focused on neuroendocrine tumors as well as cancers of the pancreas, liver, esophagus, stomach, and colon. Dr. Paulson is active in clinical research focused on neuroendocrine tumors as well as cancers of the pancreas, liver, esophagus, stomach, and colon. He currently is an investigator on a clinical trial studying nab-sirolimus, a mTOR inhibitor, which is a type of targeted therapy.TOP TEN QUESTIONS ABOUT TARGETED THERAPIES FOR NETs:1. What are targeted therapies?  Are they considered chemotherapy? How do they work?2. What are the different types of targeted therapies for NETs?3. When and how are targeted therapies used?4. What side effects might someone have when taking a targeted therapy? a.Can targeted therapies affect blood sugars or cause diabetes?b. Can targeted therapies cause one to be immunocompromised?c. Can targeted therapies affect one's blood counts?5. What is the goal of treatment with targeted therapies? (Why would one take these drugs given the potential side effects? Can the side effects be managed?)6. How do you decide which targeted therapy to recommend for a patient?7. Can a NET patient take more than one drug in this category? Can the medications be stopped and restarted?8. What is your approach with dosing?9. What is your approach with monitoring? What and how often do people need blood work?10. Does taking a targeted therapy preclude someone from getting another treatment in the future, such as Lutathera/PRRT, or a clinical trial of alpha PRRT?BONUS: What are the latest advances in targeted therapy? What is the future of targeted therapies?For more information, please visit https://www.lacnets.org/podcast/33. For more information, visit LACNETS.org.

The LACNETS Podcast - Top 10 FAQs with neuroendocrine tumor (NET) experts
Episode 32: Focus on Somatostatin Analogues (SSAs)

The LACNETS Podcast - Top 10 FAQs with neuroendocrine tumor (NET) experts

Play Episode Listen Later Apr 30, 2024 53:52


How do SSAs work? Should all NET patients be on one? What are the side effects? Dr. Edward Wolin from Mount Sinai Health System answers several common questions about the current and future role of somatostatin analogues in NET treatment. MEET Dr. EDWARD M. WOLINProfessor of Medicine, Medical Oncology, Icahn School of Medicine Director, Center for Carcinoid and Neuroendocrine Tumors Tisch Cancer Institute, Mount Sinai Health SystemDr. Edward M. Wolin is an internationally renowned authority on neuroendocrine tumors. Dr. Wolin is the Director of the Center for Carcinoid and Neuroendocrine Tumors at the Tisch Cancer Institute at Mount Sinai and Professor of Medicine, Medical Oncology at the Icahn School of Medicine at Mount Sinai.The multidisciplinary Center for Carcinoid and Neuroendocrine Tumors features a robust research program with clinical trials aimed at finding the most effective treatments, including immunotherapy, biologic agents, targeted radiation therapy, and new approaches in molecular imaging for diagnosis. Dr. Wolin has pioneered innovative therapies with novel somatostatin analogs, mTOR inhibitors, anti-angiogenic drugs, and peptide receptor radiotherapy.Prior to joining Mount Sinai, Dr. Wolin was Director of the Neuroendocrine Tumor Program at Montefiore Einstein Cancer Center. Previously, he worked for more than two decades with Cedars-Sinai Medical Center in Los Angeles, where he founded and directed one of the largest Carcinoid and Neuroendocrine Tumor Programs in the country, and subsequently directed the Neuroendocrine Tumor Program at University of Kentucky. Dr. Wolin is also the Co-Medical Director for the Carcinoid Cancer Foundation and is on the Carcinoid Cancer Research Grants Scientific Review Committee for the American Association for Cancer Research. He has published in many prestigious journals, including the New England Journal of Medicine and Journal of Clinical Oncology, and is a reviewer for numerous journals, including Journal of Clinical Oncology, Molecular Cancer Therapeutics, Clinical Cancer Research, and The Lancet Oncology.During Dr. Wolin's two decades at Cedars-Sinai Medical Center in Los Angeles, he developed a close friendship with LACNETS founder Giovanna Joyce Imbesi. Dr. Wolin was instrumental in the co-founding and development of LACNETS. LACNETS has always been very dear to his heart and he cherishes and honors the memory of Giovanna. Dr. Wolin earned his medical degree from Yale School of Medicine. He completed both his residency in internal medicine and fellowship in medical oncology at Stanford University Hospital. He was also a clinical fellow at the National Cancer Institute of the National Institutes of Health. Dr. Wolin is board certified in internal medicine and medical oncology.TOP TEN QUESTIONS ABOUT SOMATOSTATIN ANALOGUES (SSAs) FOR NETS:1. What are somatostatin analogues (SSAs)? How do they work? 2. When and how are SSAs used?3. Which SSA should a patient be on? What is the difference? How do you decide?4. How do you know if a SSA will be helpful? Should ALL NET patients be on a SSA?5. What about patients whose tumors don't “light up” on a DOTATATE scan?6. How long can someone stay on a SSA?7. What side effects may patients experience from the shot? What can patients do to prevent or manage these symptoms? How might it affect one's day-to-day ability to work and function? Can I live a “normal life” while taking this medication? 8. If the tumor is growing does this mean the SSA did not work? Do you continue it when patients are treated with another treatment? When do you stop a SSA?9. What is the future of SSAs? I heard there is a pill that is available in a clinical trial. CaFor more information, visit LACNETS.org.

The Medbullets Step 1 Podcast
Gastrointestinal | Carcinoid Tumor

The Medbullets Step 1 Podcast

Play Episode Listen Later Dec 28, 2022 16:30


In this episode, we review the high-yield topic of Carcinoid Tumor from the Gastrointestinal section. Follow Medbullets on social media: Facebook: www.facebook.com/medbullets Instagram: www.instagram.com/medbulletsofficial Twitter: www.twitter.com/medbullets --- Send in a voice message: https://anchor.fm/medbulletsstep1/message

Mayo Clinic Cardiovascular CME
Carcinoid Heart Disease - Surgical Considerations

Mayo Clinic Cardiovascular CME

Play Episode Listen Later Dec 6, 2022 9:53


Carcinoid Heart Disease - Surgical Considerations Guest: Juan A. Crestanello, M.D. Host: Malcolm R. Bell, M.D. Joining us today to discuss carcinoid heart disease (CHD) is Malcolm Bell, M.D., a professor of medicine and interventional cardiology expert and Juan Crestanello, M.D., chair of cardiovascular surgery division and professor of surgery at Mayo Clinic in Rochester, Minnesota. Tune in to learn more about carcinoid heart disease surgical considerations. Specific topics discussed: When is surgery indicated in patients with CHD? What does surgery entail and what type of valve do you use? What is the surgical risk for valve replacement and does cardiac surgery change long-term outcomes? Does carcinoid reoccur in prosthetic valves? Connect with Mayo Clinic's Cardiovascular Continuing Medical Education online at https://cveducation.mayo.edu or on Twitter @MayoClinicCV. NEW Cardiovascular Education App: The Mayo Clinic Cardiovascular CME App is an innovative educational platform that features cardiology-focused continuing medical education wherever and whenever you need it. Use this app to access other free content and browse upcoming courses. Download it for free in Apple or Google stores today! No CME credit offered for this episode. Podcast episode transcript found here.

Mayo Clinic Cardiovascular CME
Carcinoid Heart Disease

Mayo Clinic Cardiovascular CME

Play Episode Listen Later Nov 22, 2022 12:41


Carcinoid Heart Disease Guest: S. Allen Luis, M.B.B.S., Ph.D. Host: Malcolm R. Bell, M.D. Joining us today to discuss carcinoid heart disease is Malcolm Bell, M.D., a professor of medicine and interventional cardiology expert and S. Allen Luis, M.B.B.S., Ph.D., an associate professor of medicine and cardiovascular ultrasound expert at Mayo Clinic in Rochester, Minnesota. Dr. Luis specializes in the treatment of the uncommon condition, carcinoid heart disease. Tune in to learn more about the rare condition. Specific topics discussed: What is carcinoid heart disease? What valves are most affected and what are the indications to intervene for valvular disease related to carcinoid syndrome? Periprocedural carcinoid crises are associated with procedural adverse outcomes and mortality. What should be done is the periprocedural setting to minimize this risk? Connect with Mayo Clinic's Cardiovascular Continuing Medical Education online at https://cveducation.mayo.edu or on Twitter @MayoClinicCV. NEW Cardiovascular Education App: The Mayo Clinic Cardiovascular CME App is an innovative educational platform that features cardiology-focused continuing medical education wherever and whenever you need it. Use this app to access other free content and browse upcoming courses. Download it for free in Apple or Google stores today! No CME credit offered for this episode. Podcast episode transcript found here.

NETs Get Real
Overview of Pulmonary Carcinoid Tumors with Dr. Robert Ramirez

NETs Get Real

Play Episode Listen Later Oct 26, 2022 50:24


Dr. Robert Ramirez joins the show today and talks about an Overview of Pulmonary Carcinoid Tumors. He also lets us know about how he got into NETs and other important tips for patients! Please make sure to follow us on your preferred streaming platform and give us a 5 star rating! For more information please go to our website: http://www.netcancerawareness.org and follow us on social media @netcanceraware You can contact him at his email: robert.ramirez@vumc.org

The Medbullets Step 1 Podcast
Endocrine | Carcinoid Syndrome

The Medbullets Step 1 Podcast

Play Episode Listen Later Jun 6, 2022 13:01


In this episode, we review the high-yield topic of Carcinoid Syndrome from the Endocrine section. Follow Medbullets on social media: Facebook: www.facebook.com/medbullets Instagram: www.instagram.com/medbulletsofficialx Twitter: www.twitter.com/medbulletsIn this episode --- Send in a voice message: https://anchor.fm/medbulletsstep1/message

The Medbullets Step 2 & 3 Podcast
Oncology | Carcinoid Syndrome

The Medbullets Step 2 & 3 Podcast

Play Episode Listen Later Apr 27, 2022 12:26


In this episode, we review the high-yield topic of Carcinoid Syndrome from the Oncology section. Follow Medbullets on social media: Facebook: www.facebook.com/medbullets Instagram: www.instagram.com/medbulletsofficial Twitter: www.twitter.com/medbullets

Jock Doc Podcast
136. Carcinoid Syndrome/Demographic Targeting

Jock Doc Podcast

Play Episode Listen Later Jan 17, 2022 65:02


Listen as Dr. London Smith (.com) and his producer Cameron discuss Carcinoid Syndrome in a demographically specifically segmented manner. Not so boring! https://www.patreon.com/join/jockdocpodcast Hosts: London Smith, Cameron Clark. Produced by: Dylan Walker Created by: London Smith

The Well Spoken Token Podcast
Shoujo ago-gogo (Slice of Life Anime's, Jay-Z in the Hall of Fame, Scorpio Love)

The Well Spoken Token Podcast

Play Episode Listen Later Nov 3, 2021 43:10


We're not crying your crying, this week Token gives an epiphany he had on shoujo anime and slice of lifes in general. A genre he was none to ready to get into but with some sad family news he's ready to tackle. Rounding out the episode with a discussion on Hova's recent induction into the Rock n' Roll hall of fame and Dave Chappelle's introduction for the event. Its Token's birthday month and also Stomach, Lung, Carcinoid and Pancreatic cancer awareness month, hug your loved ones and if you can find a cause to support this November for the Love. Musical Guest Spot this week - Blair (@blair123XYZ)- Song title- "Needle" --- Send in a voice message: https://anchor.fm/thewellspokentoken/message Support this podcast: https://anchor.fm/thewellspokentoken/support

First Past the Post
Carcinoid Tumors

First Past the Post

Play Episode Listen Later Jan 28, 2021 1:01


This episode covers carcinoid tumors!

First Past the Post
Carcinoid Syndrome

First Past the Post

Play Episode Listen Later Jan 18, 2021 0:55


This episode covers carcinoid syndrome!

The Absite Smackdown! Podcast
Episode 46: Turkey, Tryptophan, & Carcinoid Syndrome

The Absite Smackdown! Podcast

Play Episode Listen Later Nov 22, 2020 11:25


The #ProjectSmackdownTeam discusses tryptophan, Thanksgiving, and Carcinoid Syndrome.

The European Heart Journal – Case Reports Podcast
Dr Katie Thomas discusses 'A clinical and echocardiographic case report of carcinoid-related valvular heart disease' by Ali J Ebrahimi et al.

The European Heart Journal – Case Reports Podcast

Play Episode Listen Later Nov 6, 2020 7:52


In this episode, Dr Katie Thomas discusses key points from a recent case report published in EHJ - Case Reports. 

Cardionerds
77. Case Report: Carcinoid Heart Disease with Severe Tricuspid Regurgitation – Boston University Medical Center

Cardionerds

Play Episode Listen Later Oct 28, 2020 44:31


CardioNerds (Amit Goyal & Daniel Ambinder) join Boston University cardiology fellows (Yuliya Mints, Anshul Srivastava, and Michel Ibrahim) for some hotdogs at Fenway Park in Boston, MA. They discuss an educational case of carcinoid heart disease with severe tricuspid regurgitation. Program director, Dr. Omar Siddiqi provides the E-CPR and APD Dr. Katy Bockstall provides a message for applicants. Episode notes were developed by Johns Hopkins internal medicine resident Bibin Varghese with mentorship from University of Maryland cardiology fellow Karan Desai.    Jump to: Patient summary - Case media - Case teaching - References Episode graphic by Dr. Carine Hamo The CardioNerds Cardiology Case Reports series shines light on the hidden curriculum of medical storytelling. We learn together while discussing fascinating cases in this fun, engaging, and educational format. Each episode ends with an “Expert CardioNerd Perspectives & Review” (E-CPR) for a nuanced teaching from a content expert. We truly believe that hearing about a patient is the singular theme that unifies everyone at every level, from the student to the professor emeritus. We are teaming up with the ACC FIT Section to use the #CNCR episodes to showcase CV education across the country in the era of virtual recruitment. As part of the recruitment series, each episode features fellows from a given program discussing and teaching about an interesting case as well as sharing what makes their hearts flutter about their fellowship training. The case discussion is followed by both an E-CPR segment and a message from the program director. CardioNerds Case Reports PageCardioNerds Episode PageCardioNerds AcademySubscribe to our newsletter- The HeartbeatSupport our educational mission by becoming a Patron!Cardiology Programs Twitter Group created by Dr. Nosheen Reza Patient Summary Coming soon! Case Media ABClick to Enlarge A. ECGB. TTE: CW Doppler through tricuspid valve Carcinoid - TTE 1 Carcinoid - TTE 2 Carcinoid - TTE 3 Carcinoid - TTE 4 Carcinoid - TTE 5 Carcinoid - TTE 6 Carcinoid - TTE 7 Carcinoid - TTE 8 Carcinoid - TTE 9 Episode Schematics & Teaching Coming sooN! The CardioNerds 5! – 5 major takeaways from the #CNCR case Coming soon! References Coming soon! CardioNerds Case Reports: Recruitment Edition Series Production Team Bibin Varghese, MDRick Ferraro, MDTommy Das, MDEunice Dugan, MDEvelyn Song, MDColin Blumenthal, MDKaran Desai, MDAmit Goyal, MDDaniel Ambinder, MD

Daiquiris and Dermatology
Bronchial Carcinoid Tumors

Daiquiris and Dermatology

Play Episode Listen Later Oct 24, 2020 2:25


This episode covers bronchial carcinoid tumors! --- This episode is sponsored by · Anchor: The easiest way to make a podcast. https://anchor.fm/app

Island Coolers for the Internist

This episode covers carcinoid tumors!

NETs Neuroendocrine Expert Talks
A Multidisciplinary Approach to NETs

NETs Neuroendocrine Expert Talks

Play Episode Listen Later Feb 19, 2020 18:48


Dr. Robert Ramirez, a member of the American Society of Clinical Oncology (ASCO), and NET nurse navigator Pam Ryan discuss the importance of the multidisciplinary team, building trust, and creating positive treatment experiences for patients with gastrointestinal and pancreatic NETs (GEP-NETs). (c) 2020 Ipsen Biopharmaceuticals, Inc. January 2020 SMD-US-003644

OpenAnesthesia Multimedia
Keys to the Cart: February 1, 2020

OpenAnesthesia Multimedia

Play Episode Listen Later Feb 1, 2020 4:59


Carcinoid syndrome: Definition, symptoms, and diagnosis Carcinoid syndrome: Anesthetic considerations

Radio Toilet ov Hell
Riff-Raff Podcast: Ep.37 – C Is For Coffincore

Radio Toilet ov Hell

Play Episode Listen Later Sep 20, 2019 78:12


New music from Cloud Rat, Coffins, Cognizance, Coffin Rot, and Carcinoid. We also immediately go off the rails with the new Bill & Ted's, obscure Batman villains, Hart Foundation x Deicide, solving the Boomer crisis, the Jason Suecof catch-up minute, controversial sporting takes, gun buckets, asbestos pigmen, and I confuse Grover with Gonzo. Possibly the worst thing you'll hear all week. Last week we were far more focused, played some new Nile and Updated Metal's Mascots. Listen to that before you judge us for this. Music Featured This Week: Cloud Rat - 'Wonder' from Pollinator (out now) Coffin Rot - 'Miasma Of Barbarity' from A Monument To The Dead (out 18/10 on Blood Harvest) Coffins - 'Terminate By Own Prophecy' from Beyond The Circular Demise (out 20/9 on Relapse) Cognizance - 'The Organic Citadel' from Malignant Dominion (out now on Prosthetic) Carcinoid - 'Suffering Reborn' from Metastatic Declination (out 31/10 on Blood Harvest)

NETs Neuroendocrine Expert Talks
Patient With Midgut NET

NETs Neuroendocrine Expert Talks

Play Episode Listen Later Jun 3, 2019 12:00


Dr. Jonathan Strosberg, associate professor at Moffitt Cancer Center, discusses a hypothetical patient with symptomatic carcinoid midgut NET. Dr. Strosberg provides his specific insights on practice considerations for patients having disease progression. Patient on this episode is an actor, and represents a hypothetical case. Dr. Strosberg is a paid consultant for Ipsen. ©2019 Ipsen Biopharmaceuticals, Inc. May 2019. SMD-US-002964

NETs Neuroendocrine Expert Talks
Patient With Carcinoid Syndrome

NETs Neuroendocrine Expert Talks

Play Episode Listen Later Jun 3, 2019 24:48


Dr. Daneng Li, co-director of the neuroendocrine tumor program at City of Hope National Medical Center, offers his expertise and insight on diagnosis, treatment, and dietary practices for a patient with carcinoid syndrome. Patient on this episode is an actor, and represents a hypothetical case. Dr. Li is a paid consultant for Ipsen. ©2019 Ipsen Biopharmaceuticals, Inc. May 2019. SMD-US-002859

Surgical Snippets
Appendiceal Carcinoid Podcast

Surgical Snippets

Play Episode Listen Later May 16, 2019 0:57


OpenAnesthesia Multimedia
Intraoperative TEE of the Month - May 2019

OpenAnesthesia Multimedia

Play Episode Listen Later May 1, 2019 12:12


Carcinoid heart disease

NETs Neuroendocrine Expert Talks
Patient with Pancreatic NET

NETs Neuroendocrine Expert Talks

Play Episode Listen Later Apr 10, 2019 13:24


Dr. Andrew Hendifar, medical oncology lead for the Gastrointestinal Disease Research Group at Cedars-Sinai Medical Center, discusses a hypothetical patient with nonfunctional pancreatic NET. Dr. Hendifar provides practice pointers on disease presentation, tumor characteristics, diagnosis, and a 1st-line treatment option. Patient perspectives on this episode are voiced by actors, and represent hypothetical cases. Dr. Hendifar is a paid consultant for Ipsen. © 2020 Ipsen Biopharmaceuticals, Inc. April 2020. SMD-US-003939

Real Health Stories
Episode 01 - Carcinoid Cancer: Interviewing Beth Leonard

Real Health Stories

Play Episode Listen Later Apr 30, 2018 27:14


Do you ever pause to take a look at those around you? Do you wonder what their story is, or what they have gone through? Perhaps they are more similar than appearances may lead you to believe. Here at Health Storylines, we believe that if we share people’s stories and health experiences, then it will motivate others to live their best life possible - and be more informed and motivated to make better choices. By sharing these stories with you, we hope to create a community whereby individuals encourage and empower each other by sharing their personal experiences and learnings. We hope that you will join us on our journey to shared health empowerment. Music: Summer by Ben Sound

ASCRS / DC&R podcast
DC&R: Carcinoid - Resident's Corner

ASCRS / DC&R podcast

Play Episode Listen Later Nov 24, 2017 5:35


Hear Dan Herzig, section editor of new Resident's Corner feature discuss Carcinoid with author Molly Ford.

STairs podcast
Stairs podcast 30: Carcinoid

STairs podcast

Play Episode Listen Later Nov 1, 2017


Podcast 30 är en inspelning från ST-fredagen "Anestesi vid endokrinologisk sjukdom", där Johan Nordström föreläste om Carcinoid. Platsen var Karolinska sjukhuset i Solna den 6 oktober 2017

Discovering Hope
Demand service from your Doctor! Living Life 11

Discovering Hope

Play Episode Listen Later Sep 26, 2017 7:29


Demand respect and effective treatment from your healthcare team. They work for you! Make them earn every dollar.

Discovering Hope
Demand service from your Doctor! Living Life 11

Discovering Hope

Play Episode Listen Later Sep 26, 2017 7:29


Demand respect and effective treatment from your healthcare team. They work for you! Make them earn every dollar.

ESMO 2016
Carcinoid syndrome

ESMO 2016

Play Episode Listen Later Aug 3, 2017 1:23


Dr Riechelmann speaks with ecancertv at ESMO 2016 about carcinoid syndrome, which results from carcinoid tumour invasion of organ sites and stimulation of the release of hormones. She describes the symptoms and impacts of carcinoid syndrome on patients quality of life, and introduces her review of current literature into understanding of the disease. Dr Riechelmann calls for studies into the mechanistic action and incidence of carcinoid syndrome, rather than relying on retrospective analyses.

JACC Podcast
Carcinoid Heart Disease Guidelines

JACC Podcast

Play Episode Listen Later Mar 6, 2017 23:39


Commentary by Dr. Valentin Fuster

Positivity Effect
110: Makings Lemonade With Lemons – The Wahmanns

Positivity Effect

Play Episode Listen Later Aug 30, 2016 34:09


Positivity Effect by Dr. Tom 110: Makings Lemonade With Lemons - The Wahmanns 00:00:00 00:00:00 Facebook Twitter Google Embed iTunes Making Lemonade With Lemons Robert and Maryann Wahmann are the founders of NCAN, The Neuroendocrine Cancer Awareness Network. Founded in 2004, their mission is to intensify awareness of Neuroendocrine Cancer including Carcinoid. NCAN provides access to information about NETs, and funding for NET cancer research. For the past 12 years NCAN has provided information and support to NET patients and caregivers through e-mail, our web site, and toll free phone number. Our phone line is open 7 days a week 9 am – 9 pm EST, 365 days a year! The phone line is answered by a patient or a caregiver at all times. This is very important to us . We want you to know the person on the other end of the phone understands first hand about the disease. Several thousand free information packets have been mailed worldwide. We provided many support groups worldwide with information, merchandise, awareness items and financial support. CLICK HERE for the Neuroendocrine Cancer Awareness Network NCAN’s twitter handle: @NetCancerAware On today’s episode we discuss: How Maryann’s carcinoid cancer was misdiagnosed for 7 years How a lack of information drove Robert and Maryann to found NCAN How NCAN’s conferences allow for doctors and patients to meet and discuss the disease What it takes to walk through life with a long term disease Making lemonade with lemons What it means to Robert and Maryann to be a leader Taking the road less traveled Why they encourage patients to be advocates of their own health The importance of how the delivery of a diagnosis is given What are the symptoms of  neuroendocrine cancer? How someone like Steve Jobs actually died of neuroendocrine cancer, not pancreatic   Robert and Maryann’s impact: They want to be remembered for their foundation and for making a difference in people’s lives despite the adversities that may have come their way [spp-tweet tweet=””] Another episode of the Positivity Effect goes live next Tuesday – stay tuned!! The post 110: Makings Lemonade With Lemons – The Wahmanns appeared first on The Positivity Effect.

JACC Podcast
Surgical Treatment Outcomes in Carcinoid Heart Disease

JACC Podcast

Play Episode Listen Later Nov 9, 2015 9:55


Commentary by Dr. Valentin Fuster

Video Podcasts, Lectures, and Multimedia - CTisus.com
Small Bowel Carcinoid Tumors: The Role of MDCT, 3D Imaging and CTA in Lesion Detection and Staging

Video Podcasts, Lectures, and Multimedia - CTisus.com

Play Episode Listen Later May 19, 2014


05/19/2014 | Small Bowel Carcinoid Tumors: The Role of MDCT, 3D Imaging and CTA in Lesion Detection and Staging

Medizin - Open Access LMU - Teil 20/22
The Novel Somatostatin Receptor 2/Dopamine Type 2 Receptor Chimeric Compound BIM-23A758 Decreases the Viability of Human GOT1 Midgut Carcinoid Cells

Medizin - Open Access LMU - Teil 20/22

Play Episode Listen Later Jan 1, 2013


The majority of neuroendocrine tumors (NETs) of thegastro-enteropancreatic system coexpress sornatostatin receptors (SSTRs)and dopamine type 2 receptors (D2R), thus providing a rationale for theuse of novel SSTR2/D2R chimeric compounds in NET disease. Here weinvestigate the antitumor potential of the SSTR2/D2R chimeric compoundsBIM-23A760 and BIM-23A758 in comparison to the selective SSTR2 agonistBIM-23023 and the selective D2R agonist BIM-53097 on human NET celllines of heterogeneous origin. While having only minor effects on humanpancreatic and bronchus carcinoid cells (BONI and NCI-H727), BIM-23A758induced significant antitumor effects in human midgut carcinoid cells(GOT1). These effects involved apoptosis induction as well as inhibitionof mitogen-activated protein kinase and Akt signaling. Consistent withtheir antitumor response to BIM-23A758, GOT1 cells showed relativelyhigh expression levels of SSTR2 and D2R mRNA. In particular, GOT1 cellshighly express the short transcript variant of D2R. In contrast toBIM-23A758, the SSTR2/D2R chimeric compound BIM-23A760 as well as theindividual SSTR2 and D2R agonistic compounds BIM-23023 and BIM-53097induced no or only minor antitumor responses in the examined NET celllines. Taken together, our findings suggest that the novel SSTR2/D2Rchimeric compound BIM-23A758 might be a promising substance for thetreatment of NETs highly expressing SSTR2 and D2R. In particular, asufficient expression of the short transcript variant of DR2 might playa pivotal role for effective treatment.

Video Podcasts, Lectures, and Multimedia - CTisus.com
Carcinoid Tumors of the Small Bowel: Optimization of Lesion Detection

Video Podcasts, Lectures, and Multimedia - CTisus.com

Play Episode Listen Later Jul 5, 2011


07/05/2011 | Carcinoid Tumors of the Small Bowel: Optimization of Lesion Detection

GRACEcast Lung Cancer Audio
Interview with Dr. Matthew Horton, Pathologist Part 2: Neuroendocrine Lung Tumors and Bronchioloalveolar Carcinoma (audio)

GRACEcast Lung Cancer Audio

Play Episode Listen Later Jan 28, 2010 12:30


Dr. Matthew Horton, specialist in lung pathology at CellNetix in Seattle, WA, discusses the neuroendocrine spectrum of lung tumors and the evolving views on bronchioloalveolar carcinoma (BAC).

GRACEcast Lung Cancer Video
Interview with Dr. Matthew Horton, Pathologist Part 2: Neuroendocrine Lung Tumors and Bronchioloalveolar Carcinoma (video)

GRACEcast Lung Cancer Video

Play Episode Listen Later Jan 28, 2010 12:29


Dr. Matthew Horton, specialist in lung pathology at CellNetix in Seattle, WA, discusses the neuroendocrine spectrum of lung tumors and the evolving views on bronchioloalveolar carcinoma (BAC).

DAVE Project - Gastroenterology
Video: Duodenum - Carcinoid Tumor, with EUS FNA

DAVE Project - Gastroenterology

Play Episode Listen Later Mar 25, 2009


DAVE Project - Gastroenterology
Video: Stomach - Carcinoid Tumor with EUS

DAVE Project - Gastroenterology

Play Episode Listen Later Mar 25, 2009


DAVE Project - Gastroenterology
Video: Colon - Carcinoid Tumor of the Appendix

DAVE Project - Gastroenterology

Play Episode Listen Later Jan 28, 2005


DAVE Project - Gastroenterology
Video: Colon - Carcinoid of the Rectum

DAVE Project - Gastroenterology

Play Episode Listen Later Jan 27, 2005


Medizin - Open Access LMU - Teil 12/22
Pioglitazone inhibits growth of carcinoid cells and promotes TRAIL-induced apoptosis by induction of p21(waf1/cip1)

Medizin - Open Access LMU - Teil 12/22

Play Episode Listen Later Jan 1, 2001


Background/Aims: We investigated the effect of the peroxisome proliferator-activated receptor-gamma (PPAR-gamma) agonist pioglitazone on growth and TRAIL-induced apoptosis in carcinoid cells. Methods: Carcinoid cells were incubated without and with pioglitazone. Effects on growth were examined by cell count and cell cycle analysis. p21(waf1/cip1) expression was determined by Western blotting. Cytotoxicity assay was performed by FACS analysis. Results: Pioglitazone suppressed the growth and induced apoptosis of carcinoid cells. Additionally, pioglitazone significantly enhanced carcinoid cell death induced by tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL). The enhancement of TRAIL-induced apoptosis was associated with an upregulation of cyclin-dependent kinase inhibitor p21(waf1/cip1) in pioglitazone-treated carcinoid cells. Importantly, overexpression of p21(waf1/cip1) in carcinoid cells by adenoviral gene transfer of p21 sensitized them to TRAIL-induced apoptosis. Conclusions: These results suggest that pioglitazone inhibits cell growth and sensitizes cells to TRAIL-induced apoptosis by induction of p21(waf1/cip1). Therefore, pioglitazone can be an effective therapeutic adjuvant for the treatment of carcinoid tumors. Copyright (C) 2001 S. Karger AG, Basel.